Endo Health Solutions (ENDP) subsidiary Endo Pharmaceuticals says it's returning the global rights for Urocidin to Bioniche Life Sciences. In November, Phase III clinical trials using Urocidin to treat non-muscle-invasive bladder cancer were discontinued because the trial was not recruiting at the expected rate and FDA officials had issues regarding the trials design, Endo decided to end the trial before its scheduled completion. In exchange for the return of the rights, Endo will receive a royalty on future revenue.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 5:06PM)
at Zacks.com (Mon, 10:22AM)
at Zacks.com (Mon, 8:29AM)
at MarketWatch.com (Mon, 7:57AM)
at Zacks.com (Fri, 4:18PM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs